Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.57 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16685612 | 0.81 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BDHODHPOLB | |
| SCHEMBL16613449 | 0.79 | ALDH1A1 (0.52) | ADORA2ANUDT1ADORA1DHODHADORA3 | |
| SCHEMBL16613467 | 0.77 | ALDH1A1 (0.49) | ADORA2AADORA1DHODH | |
| SCHEMBL11863107 | 0.76 | PRNP (0.51) | ADORA2AADORA1DHODHADORA3 | |
| SCHEMBL2369026 | 0.74 | ADORA2A (0.58) | ADORA2AADORA1HSP90AB1CSNK1A1CLK4 | |
| SCHEMBL30373476 | 0.74 | ADORA2A (0.58) | ADORA2AADORA1HSP90AB1CSNK1A1CLK4 | |
| SCHEMBL2368763 | 0.72 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPOLBADORA3 | |
| SCHEMBL30341167 | 0.72 | SMN1; SMN2 (0.49) | ADORA2AADORA1DHODH | |
| SCHEMBL16613484 | 0.72 | ADORA2A (0.42) | ADORA2ANUDT1ADORA1DHODHPOLB | |
| SCHEMBL421987 | 0.72 | ADORA2A (1.00) | ADORA2ANUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780343-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| EP-2036895-B9 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2013072694-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
| EP-2036895-B1 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | disclosed |
| CN-101495460-A | HSP90 inhibitor | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-07-29 | — | — | CN | disclosed |
| EP-2036895-A1 | HSP90 INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-03-18 | — | — | EP | disclosed |
| CN-100455586-C | Pyrimidothiophene compounds | VERNALIS CAMBRIDGE LTD (GB) | 2009-01-28 | — | — | CN | disclosed |
| CN-1842532-A | Pyrimidothiophene compounds | VERNALIS CAMBRIDGE LTD (GB) | 2006-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247524-A1 | HSP90 Inhibitor | HSP90AB1, HSP90B1, HSP90AA1 | ADORA2A 4662/4885NUDT1 3285/4885ADORA1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.